Miedany YE, Gaafary ME, Yassaki AE, Youssef S, Nasr A, Ahmed I. Monitoring osteoporosis therapy: Can FRAX help assessing success or failure in achieving treatment goals? World J Rheumatol 2014; 4(2): 14-21 [DOI: 10.5499/wjr.v4.i2.14]
Corresponding Author of This Article
Yasser El Miedany, MD, FRCP, Consultant Rheumatologist, Darent Valley Hospital, Dartford, Kent, DA2 8DA, United Kingdom. miedanycrd@yahoo.com
Research Domain of This Article
Rheumatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Author contributions: All authors had a substantial contribution to the conception and design of the study, drafting/revising of the article and final approval of the version to be published.
Correspondence to: Yasser El Miedany, MD, FRCP, Consultant Rheumatologist, Darent Valley Hospital, Dartford, Kent, DA2 8DA, United Kingdom. miedanycrd@yahoo.com
Telephone: +44-013-22428420 Fax: +44-013-22428415
Received: April 9, 2014 Revised: June 21, 2014 Accepted: July 5, 2014 Published online: July 12, 2014 Processing time: 156 Days and 13.2 Hours
Core Tip
Core tip: Treatment of osteoporosis should assure that the patient benefits from the treatment without experiencing undue harm. Monitoring of patients treated for osteoporosis has been recommended and so far dual-energy X-ray absorptiometry has been recognized as the tool to monitor osteoporosis therapy by several clinical practice guidelines. Recently, the duration of osteoporosis therapy became a research question with the possibility of having a drug holiday. However, more research is still needed to adequately assess when to stop the osteoporosis therapy and what is the optimal duration of the drug holiday. This work was carried out aiming at determining whether the World Health Organization fracture risk assessment tool can be used as a tool to monitor patients receiving osteoporosis treatment and to evaluate its ability to predict new low trauma fractures.
